Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mahsa S. Talbott"'
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:706-709
Autoimmune hemolytic anemia occurs due to an interaction of IgG antibodies with protein antigens expressed on red blood corpuscles. Glucocorticoids are the mainstay of treatment for autoimmune hemolytic anemia. For patients not responding to initial
Publikováno v:
European journal of haematology. 100(4)
Objective Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) in B lymphocytes as well as other kinases including interleukin-2-inducible T-cell kinase (ITK) in CD4+ Th2 regulatory T cells. Increased infections have been observed i
Autor:
Mahsa S. Talbott, James Rutledge, Cary A. Presant, Stephen A. Strickland, Michael R. Chernick, Allan Hallquist, Mathieu Perree, Anastasios Raptis
Publikováno v:
Leukemia & Lymphoma. 54:528-534
Overall survival (OS) with acute myeloid leukemia (AML) remains poor. Determining prognostic factors will help in selecting patients for appropriate treatments. Our aim was to determine whether the level of drug-induced apoptosis (chemosensitivity) d
Autor:
Mahsa S. Talbott, Megan L. Hames, Wade T. Iams, Kristy L. Richards, Nishitha Reddy, Kimberly B. Dahlman, Judy P. Tsai
As the use of lenalidomide expands, the poorly understood phenomenon of lenalidomide-induced thyroid abnormalities will increase. In this study, we compared rates of therapy-induced hypothyroidism in 329 patients with diffuse large B-cell lymphoma (D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::767507a172b9c5841d73c7286a7a4239
Autor:
David S. Morgan, Nishitha Reddy, Patrick D. Ford, Alexandra E. Kovach, John P. Greer, Mahsa S. Talbott
Publikováno v:
Blood. 128:1875-1875
Introduction: Immunotherapy with rituximab alone or in combination with sequential chemotherapy such as CHOP, in addition to a reduction in immunosuppression (IST), has been shown to be effective in achieving long-term, disease-free survival in patie
Publikováno v:
Journal of Clinical Oncology. 34:e19025-e19025
e19025Background: Ibrutinib is an oral therapeutic inhibitor of Bruton’s tyrosine kinase (BTK) with efficacy in the treatment of multiple B cell malignancies. Ibrutinib also inhibits interleukin-2-...
Publikováno v:
Leukemialymphoma. 53(8)
The diagnosis of non-Hodgkin lymphoma (NHL) is increasingly common among the elderly and it is well recognized that this patient population may benefit from therapy. No guidelines exist for chemotherapy dosing in the elderly population, and a clear a
Autor:
Kimberly B. Dahlman, Megan L. Hames, Mahsa S. Talbott, Judy P. Tsai, Wade T. Iams, Nishitha Reddy, Kristy L. Richards
Publikováno v:
Blood. 124:4438-4438
Background: The use of lenalidomide is expanding to include patients with refractory or relapsed diffuse large B cell lymphoma (DLBCL). Lenalidomide is less toxic than thalidomide, but it leads to hypothyroidism in approximately 5-10% of patients tha
Publikováno v:
OncoTargets and therapy
The peripheral T-cell lymphomas are a rare and heterogeneous group of mature T-cell lymphomas with limited available therapies. The outcome of frontline chemotherapy regimens has been disappointing, with a long-term survival of only 20%–30%. There
Autor:
Annette S. Kim, Nishitha Reddy, Meghan E Caldwell, John P. Greer, Mahsa S. Talbott, David S. Morgan, Patrick L Stevens
Publikováno v:
Blood. 118:4954-4954
Abstract 4954 Background: Standard chemotherapy with R-CHOP has a cure rate of approximately 60% for diffuse large B-cell lymphoma (DLBCL). Salvage therapy followed by autologous stem cell transplantation can cure 40–50% of patients. For patients w